Physicians' Academy for Cardiovascular Education

How do GLP-1RAs work?

5 Things a cardiologist needs to know about GLP-1RA

New - subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD – Glasgow, UK

Video navigation menu

  • GLP-1 production and glucose-stimulated insulin release 00:34
  • Mechanism of action of GLP-1RA and effect of chemical modifications 01:21
  • Effect of GLP-1RA on appetite and gastric emptying 02:29
  • Are CV benefits of GLP-1RA fully explained by observable changes in risk factors? 03:30
  • GLP-1RA CV Outcomes Trials 05:50


Show transcript

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2D and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.


Naveed Sattar, MD is Professor of Metabolic Medicine, University of Glasgow. He is an academic (active clinically) experienced in biomarker studies/trials investigating the causes, prevention and management of diabetes, obesity and heart disease.


This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Podcast of this presentation

Share this page with your colleagues and friends: